MAL-4

MAL-4 is a novel small molecule histone deacetylase (HDAC) inhibitor being developed as a potential lead drug candidate for anti-metastatic therapy in breast cancer. Developed by researchers at the University of Sharjah and the University of Freiburg, MAL-4 has demonstrated the ability to alleviate breast cancer cell growth and invasion capacity. At the molecular level, treatment with MAL-4 significantly induces the expression of tissue inhibitor of metalloproteinases 2 (TIMP-2) at both mRNA and protein levels, while reducing the expression and gelatinolytic activities of matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9). This modulation of the TIMP/MMP signaling pathway effectively attenuates the invasion capability of breast cancer cells, highlighting its potential as an effective anti-metastatic agent.